Overview

Itacitinib + Everolimus in Hodgkin Lymphoma

Status:
Recruiting

Trial end date:
2027-01-01

Target enrollment:

Participant gender:

Summary

This is an open-label, single-group, Phase I/II study of itacitinib in combination with everolimus in subjects with relapsed or refractory classical Hodgkin lymphoma (cHL).

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

University of Pennsylvania

Treatments:

Everolimus
Sirolimus